Humacyte (NASDAQ:HUMA) Issues Quarterly Earnings Results

Humacyte (NASDAQ:HUMA) released its quarterly earnings data on Friday. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07, Zacks reports.

Humacyte Trading Down 2.5 %

NASDAQ HUMA opened at $1.96 on Friday. The stock has a market cap of $246.68 million, a P/E ratio of -1.46 and a beta of 1.36. The company’s fifty day simple moving average is $3.61 and its 200-day simple moving average is $4.50. Humacyte has a 52 week low of $1.76 and a 52 week high of $9.97.

Analysts Set New Price Targets

Several research firms recently commented on HUMA. Benchmark restated a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Wednesday, March 12th. Finally, D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $13.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.